Novo Nordisk’s Alhemo Gains the CHMP’s Positive Opinion as a Prophylatic Treatment of Hemophilia A or B
Shots:
-
The CHMP has recommended Alhemo (QD, SC) as a prophylactic treatment of hemophilia A/B with inhibitors in patients (≥12yrs.), with the EC’s decision anticipated within ~2mos.
-
The opinion was based on the P-III (explorer7) study assessing the efficacy & safety of Alhemo to treat haemophilia A or B with inhibitors. Alhemo will be available in a convenient, pre-mixed, and prefilled pen upon approval
-
Alhemo (concizumab) is a mAb that blocks anti-tissue factor pathway inhibitor (TFPI) for thrombin production, preventing blood clotting
Ref: Novo Nordisk | Image: Novo Nordisk
Related News:- Novo Nordisk’s Awiqli Receives the CHMP’s Positive Opinion for the Treatment of Diabetes
PharmaShots! Your go-to media platform for customized news ranging for multiple indications. For more information connect with us at connect@pharmashots.com
A passionate content writer with expertise in delivering high-quality and engaging content, Dipanshu is a keen reader and a versatile writer. Dipanshu dedicatedly covers news ranging from biopharma, life sciences, biotech, and MedTech to diagnostics and animal health companies. He can be contacted at connect@pharmashots.com
